New insights into meningioma: From genetics to trials

Current Opinion in Oncology

Volumn 24, Issue 6, 2012, Pages 660-665

  Vranic, Andrej ^a,b   Peyre, Matthieu ^a,c,d   Kalamarides, Michel ^a,c,d  

^a Université Paris 13   (France)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BEAUJON HOSPITAL   (France)

Author keywords

angiogenesis; chemotherapy; genetics; meningioma; radiotherapy

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; IMATINIB; OCTREOTIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SUNITINIB; TRABECTEDIN;

ALLERGY; ANGIOGENESIS; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DISEASE PREDISPOSITION; DRUG EFFICACY; GENETIC ENGINEERING; HUMAN; MENINGIOMA; NONHUMAN; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SMOKING; TUMOR GROWTH;

ANIMALS; CASE-CONTROL STUDIES; CHROMOSOMAL PROTEINS, NON-HISTONE; CLINICAL TRIALS AS TOPIC; DNA-BINDING PROTEINS; GENES, NEUROFIBROMATOSIS 2; GENETIC ASSOCIATION STUDIES; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 84868201655     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283571a06     Document Type: Review

References (44)

1. Kruchko C, ed. Central brain tumor registry of the United States. Hinsdale, IL: CBTRUS; 2010. p. 32.
2. Rigau V, Zouaoui S, Mathieu-Daudé H, et al. French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathol 2011; 21:633-644.
3. Cahill KS, Claus EB. Treatment and survival of patients with nonmalignant intracranial meningioma: results from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. J Neurosurg 2011; 115:259-267.
4. van Alkemade H, de Leau M, Dieleman EM, et al. Impaired survival and longterm neurological problems in benign meningioma. Neuro Oncol 2012; 14:658-666.
5. Durand A, Labrousse F, Jouvet A, et al. WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 2009; 95:367-375.
6. Vranic A, Popovic M, Coer A, et al. Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients. Neurosurgery 2010; 67:1124-1132.
7. Claus EB, Calvocoressi L, Bondy ML, et al. Dental X-rays and risk of meningioma. Cancer 2012; 10. doi: 10.1002/cncr.26625. [Epub ahead of print]
8. Claus EB, Calvocoressi L, Bondy ML, et al. Family and personal medical history and risk of meningioma. J Neurosurg 2011; 115:1072-1077.
9. Cea-Soriano L, Blenk T, Wallander MA, Rodríguez LA. Hormonal therapies and meningioma: is there a link? Cancer Epidemiol 2012; 36:198-205.
10. Gil M, Oliva B, Timoner J, et al. Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol 2011; 72:965-968.
11. Flint-Richter P, Mandelzweig L, Oberman B, Sadetzki S. Possible interaction between ionizing radiation, smoking, and gender in the causation of meningioma. Neuro Oncol 2011; 13:345-352.
12. Goutagny S, Yang HW, Zucman-Rossi J, et al. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res 2010; 16:4155-4164.
13. Smith MJ, Higgs JE, Bowers NL, et al. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. J Med Genet 2011; 48:261-265.
14. Hadfield KD, Smith MJ, Trump D, et al. SMARCB1 mutations are not a common cause of multiple meningiomas. J Med Genet 2010; 47:567-568.
15. Christiaans I, Kenter SB, Brink HC, et al. Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. J Med Genet 2011; 48:93-97.
16. van den Munckhof P, Christiaans I, Kenter SB, et al. Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. Neurogenetics 2012; 13:1-7.
17. Dobbins SE, Broderick P, Melin B, et al. Common variation at 10p12.31 near MLLT10 influences meningioma risk. Nat Genet 2011; 43:825-827.
18. Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M, et al. Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene 2011; 30:2333-2344.
19. Preusser M, Spiegl-Kreinecker S, Lötsch D, et al. Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer 2012; 5. doi: 10.1002/cncr.27460. [Epub ahead of print]
20. Bush ML, Oblinger J, Brendel V, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol 2011; 13:983-999.
21. Andrae N, Kirches E, Hartig R, et al. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. Eur J Cancer 2012. [Epub ahead of print]
22. Nakasu S, Nakasu Y, Fukami T, et al. Growth curve analysis of asymptomatic and symptomatic meningiomas. J Neurooncol 2011; 102:303-310.
23. Oya S, Kim SH, Sade B, Lee JH. The natural history of intracranial meningiomas. J Neurosurg 2011; 114:1250-1256.
24. Kane AJ, Sughrue ME, Rutkowski MJ, et al. Anatomic location is a risk factor for atypical and malignant meningiomas. Cancer 2011; 117:1272-1278.
25. Alvernia JE, Dang ND, Sindou MP. Convexity meningiomas: study of recurrence factors with special emphasis on the cleavage plane in a series of 100 consecutive patients. J Neurosurg 2011; 115:491-498.
26. Pé rez-Magán E, Rodríguez de Lope A, Ribalta T, et al. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro Oncol 2010; 12:1278-1290.
27. Bie L, Zhao G, Ju Y, Zhang B. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence. Cancer Genet 2011; 204:536-540.
28. Lin CK, Tsai WC, Lin YC, Hueng DY. Osteopontin predicts the behaviour of atypical meningioma. Histopathology 2012; 60:320-325.
29. Johnson MD, Shaw AK, O'Connell MJ, et al. Analysis of transforming growth factor b receptor expression and signaling in higher grade meningiomas. J Neurooncol 2011; 103:277-285.
30. Schul DB, Wolf S, Krammer MJ, et al. Meningioma surgery in the elderly: outcome and validation of 2 proposed grading score systems. Neurosurgery 2012; 70:555-565.
31. Mair R, Morris K, Scott I, Carroll TA. Radiotherapy for atypical meningiomas. J Neurosurg 2011; 115:811-819.
32. Weber DC, Schneider R, Goitein G, et al. Spot scanning-based proton therapy for intracranial meningioma: long-term results from the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys 2012; 83:865-871.
33. Brokinkel B, Fischer BR, Peetz-Dienhart S, et al. MGMT promoter methylation status in anaplastic meningiomas. J Neurooncol 2010; 100:489-490.
34. Gogineni VR, Nalla AK, Gupta R, et al. Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Lett 2011; 313:64-75.
35. Reardon DA, Norden AD, Desjardins A, et al. Phase II study of Gleevec1plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol 2012; 106:409-415.
36. Schulz C, Mathieu R, Kunz U, Mauer UM. Treatment of unresectable skull base meningiomas with somatostatin analogs. Neurosurg Focus 2011; 30:11.
37. Yoshikawa A, Nakada M, Ohtsuki S, et al. Recurrent anaplastic meningioma treated by sunitinib based on results from quantitative proteomics. Neuropathol Appl Neurobiol 2012; 38:105-110.
38. Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, et al. Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16 (Ink4a) mutations. Brain Pathol 2008; 18:62-70.
39. Goutagny S, Raymond E, Sterkers O, et al. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol 2011; 22:990-991.
40. Puchner MJ, Hans VH, Harati A, et al. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol 2010; 21:2445-2446.
41. Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 2012. [Epub ahead of print]
42. Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. Neurooncol 2012. [Epub ahead of print]
43. Schmid S, Aboul-Enein F, Pfisterer W, et al. Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients. Neurosurgery 2010; 67:1703-1708.
44. Nassehi D, Dyrbye H, Andresen M, et al. Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema. APMIS 2011; 119:831-843.